Nautilus Biotechnology (NASDAQ:NAUT) Upgraded to “Strong-Buy” at Roth Capital

Roth Capital upgraded shares of Nautilus Biotechnology (NASDAQ:NAUT) to a strong-buy rating in a research note issued to investors on Tuesday morning,Zacks reports.

Other research analysts have also recently issued research reports about the company. Weiss Ratings cut Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. Leerink Partners started coverage on Nautilus Biotechnology in a research note on Wednesday, September 9th. They set an “outperform” rating and a $4.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $3.83.

Nautilus Biotechnology Trading Up 23.4%

NAUT stock opened at $1.37 on Tuesday. The stock has a market cap of $174.33 million, a PE ratio of -3.04 and a beta of 0.87. Nautilus Biotechnology has a 12 month low of $0.80 and a 12 month high of $4.31. The company has a 50-day moving average price of $1.02 and a 200 day moving average price of $2.03.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings data on Monday, July 27th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.10 million.

Institutional Investors Weigh In On Nautilus Biotechnology

Several large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of Nautilus Biotechnology during the second quarter worth approximately $5,025,000. Susquehanna International Group LLP boosted its holdings in shares of Nautilus Biotechnology by 1,710.9% in the second quarter. Susquehanna International Group LLP now owns 890,949 shares of the company’s stock valued at $1,666,000 after purchasing an additional 841,749 shares during the period. Dimensional Fund Advisors LP grew its stake in Nautilus Biotechnology by 15.3% in the first quarter. Dimensional Fund Advisors LP now owns 329,123 shares of the company’s stock worth $1,274,000 after purchasing an additional 43,684 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Nautilus Biotechnology by 2.2% during the 1st quarter. Renaissance Technologies LLC now owns 265,700 shares of the company’s stock worth $1,031,000 after purchasing an additional 5,800 shares during the period. Finally, Corient Private Wealth LP bought a new stake in Nautilus Biotechnology during the 2nd quarter valued at $308,000. 50.71% of the stock is owned by hedge funds and other institutional investors.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to help researchers study the proteome—the complete set of proteins produced by a biological system—with greater sensitivity, accuracy and throughput than conventional methods.

The company’s core offering is the Nautilus Protein Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software. The platform is designed to identify and quantify large numbers of proteins from biological samples and may support applications in drug discovery, biotechnology research, academic studies and the development of precision medicine.

Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, Washington.